Partnering
Contact
Contact Information
Join Us
EN
CN
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
Southeast Asia Business
News
Company News
Partner News
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Home
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
News
Company News
Partner News
Investors
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Partnering
Contact
Contact Information
Join Us
EN
CN
2023-09-25
Shenzhen Kangzhe Listed on the “Corporate Donation List in of 2022 Shenzhen Charitable Donation List”
Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises”
2023-09-06
Gained the Exclusive License of Cidine, an Exclusive, Marketed Oral Gastrointestinal Prokinetic Agent in China
2023-08-24
Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
2023-08-19
First Prescription of Ruxolitinib Cream for Vitiligo Announced Under Boao Super Hospital’s Early Access Program
2023-07-28
Received MSCI-ESG “AA” rating again, leading the industry globally
2023-06-29
Included in the First “Sustainability Yearbook (China)” of S&P Global
2023-06-13
The first “Diazepam Nasal Spray” Approved for Marketing in China
2023-05-31
Obtained Exclusive License of a Regenerative Medical Aesthetic Product
2023-05-30
An Innovative Drug ILUMETRI “Tildrakizumab Injection” Approved for Marketing in China
2023-05-17
Included in the “Hang Seng Innovative Drug Index”
2023-05-05
Ophthalmic Tetravalent Bispecific Antibody Product Being Granted an Approval for Drug Clinical Trial